MedPath

Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay

Completed
Conditions
Neonatal Sepsis
Registration Number
NCT01120678
Lead Sponsor
University of Virginia
Brief Summary

The purpose of this study is to determine whether analysis of specific serum biomarkers will improve the diagnosis of late onset neonatal sepsis and to determine the correlation between plasma levels of specific cytokines and bacteremia in NICU patients \>3 days of age.

Detailed Description

All infants in the Newborn Intensive Care Unit greater than three days old that had blood cultures sent were eligible for this study. Left-over blood from the time at blood culture was collected for research purposes. Study personnel separated the serum and stored samples at -80 degrees until analysis. Samples were analyzed in batch for neonatal sepsis biomarkers using an antibody-coated microsphere assay with dual laser detection. Clinical information collected included symptoms prompting the blood culture, CBC and culture results, and antibiotic therapy.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
250
Inclusion Criteria
  • NICU patients > 3 days of age
Exclusion Criteria
  • less than 3 days old or no waste blood available

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cytokine responseWithin the first twenty-four hours after blood cultures are obtained.
Secondary Outcome Measures
NameTimeMethod
Heart rate characteristicsWithin twenty-fours pre and post blood culture.

Trial Locations

Locations (2)

Wake Forest University Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

University of Virginia Neonatal Intensive Care Unit

🇺🇸

Charlottesville, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath